Guru P. Sonpavde MD
Genitourinary Oncology Director, Christopher K. Glanz Chair for Bladder Cancer Research, Assistant Director Phase I Clinical Research Unit, AdventHealth Cancer Institute, Orlando, FloridaDr. Guru Sonpavde, MD, is the Genitourinary Oncology Director at the AdventHealth Cancer Institute and the Christopher K. Glanz Chair for Bladder Cancer Research. He completed his fellowship in medical oncology and hematology at Indiana University. He leads multiple cutting-edge clinical trials studying novel immunotherapy and targeted drugs to treat urological cancers, particularly bladder cancer. He is the national or international principal investigator on multiple clinical trials for bladder cancer. He has also led translational projects and developed prognostic classifications and clinical endpoints focused on bladder cancer. He is a member of Southwest Oncology Group (SWOG) and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Cancers Steering Committee.
Disclosures
Dr. Sonpavde reports the following:
-
Advisory Board: BMS, Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics/Astellas, Astrazeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, G1 Therapeutics, Eli Lilly/Loxo Oncology, Infinity Pharmaceuticals, Lucence Health, IMV
-
Research Support: Sanofi (iaward), Astrazeneca, Gilead, Helsinn, Lucence, Predicine, BMS, EMD Serono, Jazz Therapeutics, Genecentric, Kure it, NCI (R21)
- Steering committee of studies: BMS, Bavarian Nordic, Seattle Genetics, QED, G1 Therapeutics (all unpaid), and Astrazeneca, EMD Serono, Debiopharm (paid)
- Data safety monitoring committee: Mereo
- Employment: Spouse employed by Myriad
- Writing/Editor fees: Uptodate, Editor of Elsevier Practice Update Bladder Cancer Center of Excellence
- Speaking fees: Physicians Education Resource (PER), Onclive, Research to Practice, Medscape, Cancer Network, Masters Lecture Series (MLS)
Recent Contributions to PracticeUpdate:
- ASCO 2022: Abstract Recommendations From Dr. Guru Sonpavde for Bladder Cancer
- CRP Flare Predicts Response to Anti–PD-L1 Immune Checkpoint Blockade in Metastatic Urothelial Carcinoma
- Fixed-Dose Durvalumab for Previously Treated Patients With Urinary Tract Carcinoma
- Durvalumab Plus Olaparib for Platinum-Ineligible Patients With Advanced Urothelial Carcinoma
- Pembrolizumab Plus Lenvatinib for Advanced Urothelial Carcinoma
- CV301 Vaccine Plus Atezolizumab for Advanced Urothelial Carcinoma
- Neoadjuvant Gemcitabine and Cisplatin Plus Atezolizumab in Patients With Muscle-Invasive Bladder Cancer
- 2021 Top Story in Bladder Cancer: Adjuvant Nivolumab vs Placebo in Muscle-Invasive Urothelial Carcinoma
- Incidence of Acute Kidney Injury in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma
- Significance of Serial Circulating Tumor DNA Alterations in Metastatic Urothelial Carcinoma Therapy